Merck KGaA Invests in Research Partnerships in Israel - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck KGaA Invests in Research Partnerships in Israel


Newly created company Metabomed and start-up company ChanBio joined Neviah Genomics and Merck KGaA in Merck’s Bioincubator located in Yavne, Israel, the company announced in a press release. The EUR 10 million ($13.7 million) Israel Bioincubator Fund was launched in 2011 by MS Ventures, the corporate venture arm of the prescription medicines division of Merck KGaA. The fund is focused on pre-seed and seed opportunities originating in Israel.

Merck KGaA is increasingly counting on partnerships with Israeli biotechnology companies, as demonstrated by its cooperation with Metabomed and ChanBio, the company said in the press release. Metabomed focuses on research in the field of cancer metabolism and computational biology. ChanBio will concentrate on the discovery of antibodies selective for ion channels considered to be significant therapeutic targets for the treatment of multiple sclerosis.

The biopharmaceutical division of Merck KGaA signed a memorandum of understanding earlier in November with Israel biotech company Kadimastem, which develops human pluripotent stem cell-related products. The aim is to utilize their screening platform to characterize new compounds discovered as remyelinating agents for multiple sclerosis, but also to possibly extend the collaboration into research fields such as amyotrophic lateral sclerosis. This agreement follows the signature of a previous agreement with Kadimastem in 2012.

Source: Merck

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here